RET and non-small cell lung carcinoma: The first clinical description of solvent front mutations was in a 61-year-old man with metastatic KIF5B-RET NSCLC progressing after carboplatin, pemetrexed, pembrolizumab and lenvatinib who commenced selpercatinib and had rapid clinical improvement until progression at 6 months and death at 7 months.